53
|
Patel BB, Kasneci A, Bolt AM, Di Lalla V, Di Iorio MR, Raad M, Mann KK, Chalifour LE. Chronic Exposure to Bisphenol A Reduces Successful Cardiac Remodeling After an Experimental Myocardial Infarction in Male C57bl/6n Mice. Toxicol Sci 2015; 146:101-15. [PMID: 25862758 DOI: 10.1093/toxsci/kfv073] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Estrogenic compounds such as bisphenol A (BPA) leach from plastics into food and beverage containers. Increased BPA exposure has been correlated with increased cardiovascular disease. To test the hypothesis that increased BPA exposure reduces cardiovascular remodeling, we chronically exposed C57bl/6n male mice to BPA and performed a myocardial infarction (MI). We measured cardiac function, as well as myeloid and cardiac fibroblast accumulation and activity. We found increased early death as well as increased cardiac dilation and reduced cardiac function in surviving BPA-exposed mice. Matrix metalloproteinase-2 (MMP2) protein and activity were increased 1.5-fold in BPA-exposed heart. BPA-exposed mice had similar neutrophil infiltration; however, monocyte and macrophage (MΦ) infiltration into the ischemic area was 5-fold greater than VEH mice potentially due to a 2-fold increase in monocyte chemoattractant protein-1. Monocyte and MΦ exposure to BPA in vitro in primary bone marrow cultures or in isolated peritoneal MΦ increased polarization to an activated MΦ, increased MMP2 and MMP9 expression 2-fold and activity 3-fold, and increased uptake of microspheres 3-fold. Cardiac fibroblasts (CF) differentiate to α-smooth muscle actin (αSMA) expressing myofibroblasts, migrate to the ischemic area and secrete collagen to strengthen the scar. Collagen and αSMA expression were reduced 50% in BPA-exposed hearts. Chronic in vivo or continuous in vitro BPA exposure ablated transforming growth factor beta-mediated differentiation of CF, reduced αSMA expression 50% and reduced migration 40% yet increased secreted MMP2 activity 2-fold. We conclude that chronic BPA exposure reduces the ability to successfully remodel after an MI by increasing MΦ-based inflammation and reducing myofibroblast repair function.
Collapse
Affiliation(s)
- Bhavini B Patel
- *Lady Davis Institute for Medical Research, Montréal, Québec H3T 1E2, Canada, Department of Oncology, Jewish General Hospital, 3755 Chemin Cote Ste Catherine, Montréal, Québec H3T 1E2, Canada, Division of Experimental Medicine, Department of Medicine, McGill University, 850 Sherbrooke Street, Montréal, Québec H3A 1A2, Canada, Division of Cardiology and Division of Endocrinology, Jewish General Hospital, 3755 Chemin Cote Ste Catherine, Montréal, Québec H3T 1E2, Canada
| | - Amanda Kasneci
- *Lady Davis Institute for Medical Research, Montréal, Québec H3T 1E2, Canada, Department of Oncology, Jewish General Hospital, 3755 Chemin Cote Ste Catherine, Montréal, Québec H3T 1E2, Canada, Division of Experimental Medicine, Department of Medicine, McGill University, 850 Sherbrooke Street, Montréal, Québec H3A 1A2, Canada, Division of Cardiology and Division of Endocrinology, Jewish General Hospital, 3755 Chemin Cote Ste Catherine, Montréal, Québec H3T 1E2, Canada
| | - Alicia M Bolt
- *Lady Davis Institute for Medical Research, Montréal, Québec H3T 1E2, Canada, Department of Oncology, Jewish General Hospital, 3755 Chemin Cote Ste Catherine, Montréal, Québec H3T 1E2, Canada, Division of Experimental Medicine, Department of Medicine, McGill University, 850 Sherbrooke Street, Montréal, Québec H3A 1A2, Canada, Division of Cardiology and Division of Endocrinology, Jewish General Hospital, 3755 Chemin Cote Ste Catherine, Montréal, Québec H3T 1E2, Canada *Lady Davis Institute for Medical Research, Montréal, Québec H3T 1E2, Canada, Department of Oncology, Jewish General Hospital, 3755 Chemin Cote Ste Catherine, Montréal, Québec H3T 1E2, Canada, Division of Experimental Medicine, Department of Medicine, McGill University, 850 Sherbrooke Street, Montréal, Québec H3A 1A2, Canada, Division of Cardiology and Division of Endocrinology, Jewish General Hospital, 3755 Chemin Cote Ste Catherine, Montréal, Québec H3T 1E2, Canada
| | - Vanessa Di Lalla
- *Lady Davis Institute for Medical Research, Montréal, Québec H3T 1E2, Canada, Department of Oncology, Jewish General Hospital, 3755 Chemin Cote Ste Catherine, Montréal, Québec H3T 1E2, Canada, Division of Experimental Medicine, Department of Medicine, McGill University, 850 Sherbrooke Street, Montréal, Québec H3A 1A2, Canada, Division of Cardiology and Division of Endocrinology, Jewish General Hospital, 3755 Chemin Cote Ste Catherine, Montréal, Québec H3T 1E2, Canada
| | - Massimo R Di Iorio
- *Lady Davis Institute for Medical Research, Montréal, Québec H3T 1E2, Canada, Department of Oncology, Jewish General Hospital, 3755 Chemin Cote Ste Catherine, Montréal, Québec H3T 1E2, Canada, Division of Experimental Medicine, Department of Medicine, McGill University, 850 Sherbrooke Street, Montréal, Québec H3A 1A2, Canada, Division of Cardiology and Division of Endocrinology, Jewish General Hospital, 3755 Chemin Cote Ste Catherine, Montréal, Québec H3T 1E2, Canada
| | - Mohamad Raad
- *Lady Davis Institute for Medical Research, Montréal, Québec H3T 1E2, Canada, Department of Oncology, Jewish General Hospital, 3755 Chemin Cote Ste Catherine, Montréal, Québec H3T 1E2, Canada, Division of Experimental Medicine, Department of Medicine, McGill University, 850 Sherbrooke Street, Montréal, Québec H3A 1A2, Canada, Division of Cardiology and Division of Endocrinology, Jewish General Hospital, 3755 Chemin Cote Ste Catherine, Montréal, Québec H3T 1E2, Canada
| | - Koren K Mann
- *Lady Davis Institute for Medical Research, Montréal, Québec H3T 1E2, Canada, Department of Oncology, Jewish General Hospital, 3755 Chemin Cote Ste Catherine, Montréal, Québec H3T 1E2, Canada, Division of Experimental Medicine, Department of Medicine, McGill University, 850 Sherbrooke Street, Montréal, Québec H3A 1A2, Canada, Division of Cardiology and Division of Endocrinology, Jewish General Hospital, 3755 Chemin Cote Ste Catherine, Montréal, Québec H3T 1E2, Canada *Lady Davis Institute for Medical Research, Montréal, Québec H3T 1E2, Canada, Department of Oncology, Jewish General Hospital, 3755 Chemin Cote Ste Catherine, Montréal, Québec H3T 1E2, Canada, Division of Experimental Medicine, Department of Medicine, McGill University, 850 Sherbrooke Street, Montréal, Québec H3A 1A2, Canada, Division of Cardiology and Division of Endocrinology, Jewish General Hospital, 3755 Chemin Cote Ste Catherine, Montréal, Québec H3T 1E2, Canada *Lady Davis Institute for Medical Research, Montréal, Québec H3T 1E2, Canada, Department of Oncology, Jewish General Hospital, 3755 Chemin Cote Ste Catherine, Montréal, Québec H3T 1E2, Canada, Division of Experimental Medicine, Department of Medicine, McGill University, 850 Sherbrooke Street, Montréal, Québec H3A 1A2, Canada, Division of Cardiology and Division of Endocrinology, Jewish General Hospital, 3755 Chemin Cote Ste Catherine, Montréal, Québec H3T 1E2, Canada
| | - Lorraine E Chalifour
- *Lady Davis Institute for Medical Research, Montréal, Québec H3T 1E2, Canada, Department of Oncology, Jewish General Hospital, 3755 Chemin Cote Ste Catherine, Montréal, Québec H3T 1E2, Canada, Division of Experimental Medicine, Department of Medicine, McGill University, 850 Sherbrooke Street, Montréal, Québec H3A 1A2, Canada, Division of Cardiology and Division of Endocrinology, Jewish General Hospital, 3755 Chemin Cote Ste Catherine, Montréal, Québec H3T 1E2, Canada *Lady Davis Institute for Medical Research, Montréal, Québec H3T 1E2, Canada, Department of Oncology, Jewish General Hospital, 3755 Chemin Cote Ste Catherine, Montréal, Québec H3T 1E2, Canada, Division of Experimental Medicine, Department of Medicine, McGill University, 850 Sherbrooke Street, Montréal, Québec H3A 1A2, Canada, Division of Cardiology and Division of Endocrinology, Jewish General Hospital, 3755 Chemin Cote Ste Catherine, Montréal, Québec H3T 1E2, Canada *Lady Davis Institute for Medical Research, Montréal, Québec H3T 1E2, Canada, Department of Oncology, Jewish General Hospital, 3755 Chemin Cote Ste Catherine, Montréal, Québec H3T 1E2, Canada, Division of Experimental Medicine, Department of Medicine, McGill University, 850 Sherbrooke Street, Montréal, Québec H3A 1A2, Canada, Division of Cardiology and Division of Endocrinology, Jewish General Hospital, 3755 Chemin Cote Ste Catherine, Montréal, Québec H3T 1E2, Canada *Lady Davis Institute for Medical Research, Montréal, Québec H3T 1E2, Canada, Department of Oncology, Jewish General Hospital, 3755 Chemin Cote Ste Catherine, Montréal, Québec H3T 1E2, Canada, Division of Experimental Medicine, Department of Medicine, McGill University, 850 Sherbrooke Street, Montréal, Québec H3A 1A2, Canada, Division of Cardiology and Division of Endocrinology, Jewish General Hospital, 3755 Chemin Cote Ste Catherine, Montréal, Québec H3T 1E2, Canada
| |
Collapse
|
56
|
Spanier AJ, Kahn RS, Kunselman AR, Schaefer EW, Hornung R, Xu Y, Calafat AM, Lanphear BP. Bisphenol a exposure and the development of wheeze and lung function in children through age 5 years. JAMA Pediatr 2014; 168:1131-7. [PMID: 25286153 PMCID: PMC4535321 DOI: 10.1001/jamapediatrics.2014.1397] [Citation(s) in RCA: 57] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
IMPORTANCE Bisphenol A (BPA), a prevalent endocrine-disrupting chemical, has been associated with wheezing in children, but few studies have examined its effect on lung function or wheeze in older children. OBJECTIVES To test whether BPA exposure is associated with lung function, with wheeze, and with pattern of wheeze in children during their first 5 years. DESIGN, SETTING, AND PARTICIPANTS A birth cohort study, enrolled during early pregnancy in the greater Cincinnati, Ohio, area among 398 mother-infant dyads. We collected maternal urine samples during pregnancy (at 16 and 26 weeks) and child urine samples annually to assess gestational and child BPA exposure. MAIN OUTCOMES AND MEASURES We assessed parent-reported wheeze every 6 months for 5 years and measured child forced expiratory volume in the first second of expiration (FEV1) at age 4 and 5 years. We evaluated associations of BPA exposure with respiratory outcomes, including FEV1, child wheeze, and wheeze phenotype. RESULTS Urinary BPA concentrations and FEV1 data were available for 208 children and urinary BPA concentrations and parent-reported wheeze data were available for 360 children. The mean maternal urinary BPA concentration ranged from 0.53 to 293.55 µg/g of creatinine. In multivariable analysis, every 10-fold increase in the mean maternal urinary BPA concentration was associated with a 14.2% (95% CI, -24.5% to -3.9%) decrease in the percentage predicted FEV1 at 4 years, but no association was found at 5 years. In multivariable analysis, every 10-fold increase in the mean maternal urinary BPA concentration was marginally associated with a 54.8% increase in the odds of wheezing (adjusted odds ratio, 1.55; 95% CI, 0.91-2.63). While the mean maternal urinary BPA concentration was not associated with wheeze phenotype, a 10-fold increase in the 16-week maternal urinary BPA concentration was associated with a 4.27-fold increase in the odds of persistent wheeze (adjusted odds ratio, 4.27; 95% CI, 1.37-13.30). Child urinary BPA concentrations were not associated with FEV1 or wheeze. CONCLUSIONS AND RELEVANCE These results provide evidence suggesting that prenatal but not postnatal exposure to BPA is associated with diminished lung function and the development of persistent wheeze in children.
Collapse
Affiliation(s)
- Adam J. Spanier
- Department of Pediatrics, Penn State University Hershey Medical Center, Hershey, PA,Department of Public Health Sciences, Penn State University Hershey Medical Center, Hershey, PA
| | - Robert S. Kahn
- Department of Pediatrics, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio
| | - Allen R. Kunselman
- Department of Public Health Sciences, Penn State University Hershey Medical Center, Hershey, PA
| | - Eric W. Schaefer
- Department of Public Health Sciences, Penn State University Hershey Medical Center, Hershey, PA
| | - Richard Hornung
- Department of Pediatrics, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio
| | - Yingying Xu
- Department of Pediatrics, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio
| | - Antonia M. Calafat
- Division of Laboratory Sciences, National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta GA
| | - Bruce P. Lanphear
- Child and Family Research Institute, BC Children’s Hospital and Faculty of Health Sciences, Simon Fraser University, Vancouver, Canada
| |
Collapse
|